Lexicon’s AAK1 inhibitor disappoints in Phase II postherpetic neuralgia study
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
About BioSpace
This author has yet to write their bio.Meanwhile lets just say that we are proud BioSpace contributed a whooping 5020 entries.
Entries by BioSpace
Two Biotech CEOs charged in securities fraud schemes
The federal indictment alleged the two executives engaged in “false and misleading representations and material omissions” regarding the development of experimental monoclonal antibody leronlimab.
BioSpace’s top clinical advancements of 2022
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
Pfizer doubles down on AI/ML to bring transformative medicines to patients
The vision is three-fold: uncover disease biology with AI; use these insights to design the right molecules; determine the right patient population for clinical trial success.
FDA places clinical hold on Entrada’s IND for Duchenne Muscular Dystrophy
Entrada Therapeutics said it received a clinical hold notice from the regulatory agency but no reason was provided. “We are eager to resolve this hold and continue down the treatment development pathway,” President and CEO Dipal Doshi said.
Novartis’ restructuring claims 285 jobs in New Jersey
The job cuts will span three business units – Novartis Pharmaceuticals, Novartis Services Inc., and Novartis Corporation – with terminations taking effect on January 28, 2023.
Sanofi deepens NK cell therapy partnership with Innate Pharma
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
It’s a new day in neuropsychiatrics
Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.
Lilly plunks down up to $731M in GPCR pact with Sosei
The company has entered into a multi-target partnership with Sosei Group to discover, develop and commercialize compounds targeting novel G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.
In second pipeline pivot, Axcella axes 85% of staff
In a strategic reorganization announced Thursday, Axcella Therapeutics will focus its resources on its Long COVID program and slash headcount by 85%.
